

**bs-18604R****[ Primary Antibody ]****LY6D Rabbit pAb**

www.bioss.com.cn

sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

**— DATASHEET —**

<b>Host:</b> Rabbit	<b>Isotype:</b> IgG	<b>Applications:</b> <b>IHC-P</b> (1:100-500) <b>IHC-F</b> (1:100-500) <b>IF</b> (1:100-500) <b>ICC/IF</b> (1:100-500) <b>ELISA</b> (1:5000-10000)  <b>Reactivity:</b> Human  <b>Predicted MW.:</b> 8.4 kDa  <b>Subcellular Location:</b> Cell membrane
<b>Clonality:</b> Polyclonal		
<b>GeneID:</b> 8581	<b>SWISS:</b> Q14210	
<b>Target:</b> LY6D		
<b>Immunogen:</b> KLH conjugated synthetic peptide derived from human LY6D: 41-128/128.		
<b>Purification:</b> affinity purified by Protein A		
<b>Concentration:</b> 1mg/ml		
<b>Storage:</b> 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.		
<b>Background:</b> Ly-6D is a 128 amino acid glycoprotein that is expressed in squamous cell carcinoma cell lines and squamous cell epithelia tissue. Ly-6D contains a signal peptide, 2 theoretical phosphorylation sites and 3 putative myristoylation sites. Upregulation of the gene encoding Ly-6D in head and neck cancers is associated with poor prognosis and high expression of Ly-6D has been linked to enhanced cell migration. Ly-6D is frequently used as a molecular marker for diagnosis and therapy of head-and-neck squamous cell carcinoma (HNSCC). It has been suggested that Ly-6D may regulate the expression levels of certain fucosylated E-selectin ligands and protein FX, a protein that contributes to the last step in the synthesis of GDP-L-fucose, in HNSCC cell lines. This finding is indicative that Ly-6D may regulate tumor cell adhesion in inflamed vessel walls that express E-selectin.		